Vivos Therapeutics (NASDAQ:VVOS) Posts Quarterly Earnings Results

Vivos Therapeutics (NASDAQ:VVOS) released its quarterly earnings data on Wednesday. The company reported ($0.58) earnings per share (EPS) for the quarter, Zacks reports. The company had revenue of $3.82 million for the quarter. Vivos Therapeutics had a negative net margin of 98.77% and a negative return on equity of 351.28%.

Vivos Therapeutics Stock Performance

Shares of VVOS traded up $0.12 during mid-day trading on Wednesday, reaching $1.47. 390,860 shares of the company’s stock traded hands, compared to its average volume of 172,194. The company has a debt-to-equity ratio of 3.31, a quick ratio of 0.78 and a current ratio of 0.78. The business’s 50-day moving average price is $1.37 and its 200-day moving average price is $2.01. The stock has a market capitalization of $15.39 million, a P/E ratio of -0.83 and a beta of 6.93. Vivos Therapeutics has a 12 month low of $1.09 and a 12 month high of $7.95.

Insider Transactions at Vivos Therapeutics

In other Vivos Therapeutics news, major shareholder Michael C. Skaff bought 1,353,625 shares of the business’s stock in a transaction on Tuesday, March 31st. The shares were purchased at an average price of $1.34 per share, with a total value of $1,813,857.50. Following the purchase, the insider directly owned 1,353,625 shares of the company’s stock, valued at approximately $1,813,857.50. The trade was a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 2.10% of the stock is owned by company insiders.

Hedge Funds Weigh In On Vivos Therapeutics

Several hedge funds have recently modified their holdings of the company. DRW Securities LLC boosted its position in shares of Vivos Therapeutics by 179.5% in the 4th quarter. DRW Securities LLC now owns 115,907 shares of the company’s stock valued at $235,000 after purchasing an additional 74,441 shares during the period. Connective Capital Management LLC acquired a new stake in Vivos Therapeutics during the 3rd quarter worth about $620,000. B. Riley Wealth Advisors Inc. purchased a new stake in Vivos Therapeutics during the second quarter valued at about $220,000. Finally, XTX Topco Ltd acquired a new position in shares of Vivos Therapeutics in the second quarter worth about $65,000. 26.35% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Vivos Therapeutics in a research note on Wednesday, January 21st. Two investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $4.92.

Vivos Therapeutics Company Profile

Vivos Therapeutics, Inc is a medical technology company focused on the development and commercialization of oral appliance therapy for the treatment of obstructive sleep apnea (OSA) and other airway-related disorders. The company’s proprietary Vivos System integrates clinical diagnostic protocols, three-dimensional imaging, and custom-designed dental appliances to address mild to moderate forms of sleep-disordered breathing through non-surgical, non-invasive means.

The Vivos System comprises a range of custom oral devices, digital workflow tools, and a structured treatment protocol.